{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:14:21Z","timestamp":1757452461012},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.eururo.2018.09.043","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:45:02Z","timestamp":1540323902000},"page":"240-241","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers"],"prefix":"10.1016","volume":"75","author":[{"given":"Woonyoung","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2018.09.043_bib0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2018.09.043_bib0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.043_bib0070","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2018.09.043_bib0075","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.043_bib0080","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2018.09.043_bib0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.043_bib0090","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2018.09.043_bib0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2018.09.043_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2018.09.043_bib0105","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2018.09.043_bib0110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818307322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283818307322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T21:43:36Z","timestamp":1547588616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283818307322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0302283818307322"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.043","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2018.09.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}